Previous 10 | Next 10 |
New ARCT-154 clinical booster data demonstrate promising durability; 44- and 39-fold increases in neutralizing antibody response against Omicron BA.1 and BA.2 at Day 91 New cold chain data for Arcturus’ lyophilized vaccine platform shows favorable stability, shipping, a...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory r...
Gainers: Rhythm Pharmaceuticals ( RYTM ) +20% . Allakos ( ALLK ) +14% . Senti Biosciences ( SNTI ) +13% . Arcturus Therapeutics ( ARCT ) +7% . Verve Therapeutics ( VERV ) +5% . Losers: Vascular Biogenics ( VBLT ) -78%...
ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...
Gainers: Inter & ( INTR ) +34% . Cytokinetics ( CYTK ) +6% . MSP Recovery ( MSPR ) +6% . Ocular Therapeutix ( OCUL ) +5% . Kirkland's ( KIRK ) +5% . Losers: Microvast Holdings ( MVST ) -7% . Virgin O...
Arcturus Therapeutics (NASDAQ:ARCT) is said to have been approached about a takeover by CSL Limited (OTCPK:CSLLY), a source reportedly told Street Insider, whose account added that it is "unclear if the rumored talks will lead to a definitive deal." Shares of Arcturus was up 8% on take o...
An EUA for ARCT-154 as a COVID-19 vaccine in Vietnam has been submitted, with expected approval in 2022. A phase 2 study using ARCT-810 as a treatment option for patients with OTC deficiency is expected to start in mid-2022; results are then expected 2nd half of 2022. A CTA to beg...
Gainers: Avadel Pharmaceuticals (AVDL) +123%. SIGA Technologies (SIGA) +40%. Concert Pharmaceuticals (CNCE) +30%. Farfetch (FTCH) +25%. Allarity Therapeutics (ALLR) +25%. Merus N.V. (MRUS) +23%. Tenon Medical (TNON) +22%. Arcturus Therapeutics Holdings (ARCT) +19%. Red Rob...
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2022 Results Earnings Conference Call May 9, 2022, 04:30 PM ET Company Participants Deepankar Roy - Senior Director, Investor Relations Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Pad Chivukula - C...
Arcturus Therapeutics press release (NASDAQ:ARCT): Q1 GAAP EPS of -$1.94 misses by $0.63. Revenue of $5.24M (+146.0% Y/Y) misses by $1.84M. For further details see: Arcturus Therapeutics GAAP EPS of -$1.94 misses by $0.63, revenue of $5.24M misses by $1.84M
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...